Principal Advisor: Professor Brian Gabrielli


Phone: 0434 602 061

Organisational unit: Mater Research Institute-UQ

The success of immunotherapies has demonstrated that harnessing the patient’s immune system to combat their cancer is a feasible strategy that can lead to long term remissions. However, cancer has developed a wide range of strategies to avoid immune surveillance. We have found that by using drugs that selectively target defects in cancers the result increased DNA damage and cell death we can overcome the immune suppressive mechanisms of cancer to promote enhanced anti-cancer immune responses. There are projects available to investigate these approaches working in the intersection between cancer cell biology and immunology.

Register your interest